Skip to main content
TrimSoMoEverything GLP-1, in one place
Program Profile

NovoCare

Is NovoCare listed in FDA warning letters?

No FDA warning letters addressed to NovoCare appear in our dataset (FDA.gov letters 2023–2026). FDA has issued 2 warning letters to the manufacturer, Novo Nordisk Inc.: 2026-03-05, 2025-09-09. Subjects named in the FDA records: "Postmarketing Adverse Drug Experience Reporting Requirements" and "False & Misleading Claims/Misbranded".

Key facts

  • •Care model: Manufacturer self-pay and access program.
  • •Medications discussed: Wegovy (semaglutide), Wegovy Tablets (oral semaglutide), Saxenda (liraglutide).
  • •State availability: Confirm directly with program. Note: The reviewed program page did not provide a state availability list. Confirm service and dispensing availability directly.

Manufacturer self-pay program for Wegovy. It is a way to fill a prescription, not a doctor-service plan.

At a glance
Care model
Manufacturer self-pay program
Medications discussed
Wegovy (semaglutide), Wegovy Tablets (oral semaglutide), Saxenda (liraglutide)
Availability
Confirm with program
The reviewed program page did not provide a state availability list. Confirm service and dispensing availability directly.

FDA Warning Letter Records Identified

NovoCare is the patient assistance and affordability portal operated by manufacturer Novo Nordisk Inc. Official FDA warning letters issued to the parent manufacturer concerning promotional materials and postmarketing reporting are detailed below.

Novo Nordisk Inc.

Center for Drug Evaluation and Research (CDER)

Issued: 2026-03-05

Subject: Postmarketing Adverse Drug Experience Reporting Requirements

Failure to develop adequate written PADE procedures (21 CFR 314.80(b))Failure to report serious and unexpected ADEs within 15 calendar days (21 CFR 314.80(c)(1)(i))Improper rejection or invalidation of serious and unexpected ADE casesFailure to ensure contractor and vendor compliance with PADE requirementsIneffective corrective and preventive actions

FDA says nNI's written PADE procedures allowed rejection of serious unexpected ADEs based on reporter causality, invalidated cases lacking patient identifiers, and let cases stall in medical review, causing late or missed 15-day reports.

Novo Nordisk Inc.

Center for Drug Evaluation and Research (CDER)

Issued: 2025-09-09

Subject: False & Misleading Claims/Misbranded

false or misleading promotional communicationmisbrandingomission and minimization of serious risk informationfailure to submit promotional materials at time of initial dissemination (21 CFR 314.81(b)(3)(i))

FDA says a video titled "An Oprah Special: Shame, Blame, and the Weight Loss Revolution" omitted and minimized serious risks, including the boxed warning for thyroid C-cell tumors, misbranding Wegovy, Ozempic, and Victoza, and that the video was not submitted to FDA on Form FDA-2253 at initial publication.

Questions to ask the program

Before you use this program

This is a manufacturer self-pay program for filling a prescription, not a care program. Read its terms on its own website.

  • •Is a prescription from your own clinician required?
  • •Which pharmacy fills the prescription, and how is it delivered?
  • •Who do you contact with questions about an order?
Sources

Source records

NovoCare website

Last checked Nov 4, 2026

Open original source

NovoCare Wegovy Online Pharmacy & Delivery page

Last checked Nov 7, 2026

Open original source
Pre-Enrollment Verification

Evaluate Eligibility & Coverage Before Enrolling in NovoCare

Check manufacturer copay card rules, federal program exclusions, and cash-pay vial terms for NovoCare.

All Decision Tools
Financial Modeling

Copay & Savings Card Rules

Model out-of-pocket copays for Zepbound and Wegovy under commercial plans ($25/mo caps) vs. self-pay cash channels.

Clinical Prep

Baseline Lab & Safety Screen

Legitimate telehealth prescribers require baseline kidney and A1c bloodwork. Review required panels and boxed warnings before your intake.

Indication Check

FDA BMI Indication Gauge

Verify whether your BMI meets official FDA prescribing standards (BMI ≥30 or ≥27 with comorbidity) before paying non-refundable fees.

100% Client-Side Privacy: No personal health data is shared with providers or third parties.Independent consumer guidance based on official DailyMed FDA prescribing archives.
Patient Guidance & Safety

Telehealth Navigation & Checklist

Evaluating a digital clinic? Review our clinical checklists for verifying state licensure, required blood work, and navigating insurance coverage.

Notice outdated or missing information? Submit a source-linked correction request.